经循环肿瘤DNA检测评估EGFR敏感变异的临床诊断晚期肺癌患者接受埃克替尼治疗的临床结局评价:一项2期非随机临床试验
CHALLENGE试验为前瞻性、多中心、开放标签、单臂2期非随机临床试验,纳入116例未经系统治疗、临床诊断晚期周围型肺癌且病理状态未知、治疗前血浆EGFR敏感变异阳性的中国患者,一线口服埃克替尼125 mg每日3次。客观缓解率52.6%(95%CI 43.1%-61.9%),中位无进展生存期10.3个月(95%CI 8.3-12.2),中位总生存期23.2个月(95%CI 17.7-28.0),疾病控制率84.5%(95%CI 76.6%-90.5%)。
要点
- 临床诊断晚期肺癌且病理未知、ctDNA EGFR敏感变异阳性者,一线埃克替尼客观缓解率52.6%。
- 中位无进展生存期10.3个月,中位总生存期23.2个月,疾病控制率84.5%。
- 3个检测平台一致率80.1%(313/391),任一平台阳性者临床结局相当。
核心结论
- 该前瞻性2期非随机临床试验提示,对临床诊断晚期肺癌且病理状态未知的患者,基于ctDNA的EGFR基因分型可有助于特定临床情境下的决策,但仍需未来更大规模的真实世界探索。
研究设计与样本
- CHALLENGE试验为前瞻性、多中心、开放标签、单臂2期非随机临床试验,于2017年7月1日至2019年7月31日开展。
- 自中国19个中心筛查391例可能合格的中国患者,采用3个独立检测平台(SuperARMS聚合酶链反应、微滴数字聚合酶链反应、下一代测序)检测ctDNA EGFR变异,任一平台检出EGFR变异者纳入。
- 共纳入116例未经系统治疗、临床诊断晚期周围型肺癌、病理状态未知且治疗前血浆EGFR敏感变异阳性的患者。
- 入组患者口服埃克替尼片125 mg每日3次,直至疾病进展、死亡或因毒性反应、撤回知情同意等各种原因终止治疗。
主要发现
- 116例纳入患者中76例(65.5%)为女性,中位(范围)年龄64(37-85)岁,中位(IQR)随访时间36.3(30.2-40.7)个月。
- 客观缓解率为52.6%(95%CI 43.1%-61.9%)。
- 中位无进展生存期为10.3个月(95%CI 8.3-12.2),中位总生存期为23.2个月(95%CI 17.7-28.0)。
- 疾病控制率为84.5%(95%CI 76.6%-90.5%)。
- 3个检测平台间一致率为80.1%(313/391),任一平台判定为阳性的患者临床结局相当。
关键数值与推荐
- 主要终点为客观缓解率,次要终点包括无进展生存期、总生存期、疾病控制率及3个检测平台间的一致性。
- 客观缓解率52.6%(95%CI 43.1%-61.9%),疾病控制率84.5%(95%CI 76.6%-90.5%)。
- 中位无进展生存期10.3个月(95%CI 8.3-12.2),中位总生存期23.2个月(95%CI 17.7-28.0)。
- 3个检测平台一致率80.1%(313/391)。
临床怎么用
- 作者认为,对临床诊断晚期肺癌且病理状态未知的患者,基于ctDNA的EGFR基因分型可有助于特定临床情境下的决策,但仍需未来更大规模的真实世界探索。
局限性
- 原文结论指出仍需要未来更大规模的真实世界探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The inability to obtain a pathological diagnosis in a certain proportion of patients with clinically diagnosed advanced lung cancer impedes precision treatment in clinical practice. OBJECTIVE: To evaluate the clinical outcome of first-line icotinib in patients with clinically diagnosed advanced lung cancer with unknown pathological status and positive epidermal growth factor receptor (EGFR)-sensitizing variants assessed by circulating tumor DNA (ctDNA). DESIGN, SETTING, AND PARTICIPANTS: The Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-Positive Patients Diagnosed With Lung Cancer (CHALLENGE) trial is a prospective, multicentered, open-label, single-arm phase 2 nonrandomized clinical trial conducted between July 1, 2017, and July 31, 2019. Patients with systemic treatment-naive, clinically diagnosed advanced peripheral lung cancer, unknown pathological status, and positive pretreatment plasma EGFR-sensitizing variants were eligible. A total of 391 potentially eligible Chinese patients from 19 centers in China were screened for ctDNA EGFR variants by 3 independent detection platforms (Super amplification refractory mutation system [SuperARMS] polymerase chain reaction, droplet digital polymerase chain reaction, and next-generation sequencing), and those with EGFR variants tested by any platform were included. Analyses were conducted from September 9 to December 31, 2021. INTERVENTIONS: Enrolled patients were treated with oral icotinib tablets (125 mg 3 times daily) until disease progression, death, or treatment discontinuation due to various reasons, such as toxic effects and withdrawing consent. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and the concordance among the 3 detection platforms. RESULTS: Of 116 included patients, 76 (65.5%) were female, and the median (range) age was 64 (37-85) years. The median (IQR) follow-up duration was 36.3 (30.2-40.7) months. The ORR was 52.6% (95% CI, 43.1%-61.9%). The median PFS and OS were 10.3 months (95% CI, 8.3-12.2) and 23.2 months (95% CI, 17.7-28.0), respectively, and the DCR was 84.5% (95% CI, 76.6%-90.5%). The concordance rate among the 3 detection platforms was 80.1% (313 of 391), and the clinical outcomes in patients identified as positive by any platform were comparable. CONCLUSIONS AND RELEVANCE: This prospective phase 2 nonrandomized clinical trial suggests that for patients with clinically diagnosed advanced lung cancer with unknown pathological status, ctDNA-based EGFR genotyping could help decision-making in particular clinical situations, while still warranting future larger-scaled real-world exploration. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03346811.
引用
- Xu J, Liu Z, Bai H, et al. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022. PMID: 35862035. doi:10.1001/jamaoncol.2022.2719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。